Compare Amphastar Pharmaceuticals Inc (AMPH) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Deckers Outdoor Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Deckers Outdoor Corp trades at $107.48 (market cap $14.72B). The key difference: Deckers Outdoor Corp is far larger — about 17.8× Amphastar Pharmaceuticals Inc's market cap, and Deckers Outdoor Corp is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | DECK | |
|---|---|---|
Market Cap | $826.08M | $14.72B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $123.91 |
52-Week Low | $16.87 | $79.54 |
Enterprise Value | $1.22B | $13.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
DECK trades at $105.99, up 1.66% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.99B in 2025, with net income reaching $966M and profit margin expanding to 19.37%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.96 versus $0.83 expected. Cash flow from operations remains robust at $1.04B, supporting financial stability.
The stock offers upside to the $121.50 consensus price target, driven by HOKA and UGG global growth. Risks include competitive pressures and volatile technical indicators. Analyst sentiment is mixed with 41.82% buy ratings, but institutional holdings suggest long-term confidence amid near-term bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
